Shlevin Harold H. 4
4 · GALECTIN THERAPEUTICS INC · Filed Dec 16, 2025
Insider Transaction Report
Form 4
Shlevin Harold H.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-12$4.16/sh+19,793$82,339→ 30,999 total - Sale
Common Stock
2025-12-12$6.27/sh−19,793$124,181→ 11,206 total - Exercise/Conversion
Common Stok
2025-12-15$4.16/sh+8,417$35,015→ 19,623 total - Sale
Common Stock
2025-12-15$6.30/sh−8,417$53,027→ 11,206 total - Exercise/Conversion
Stock Option (right to buy)
2025-12-12−19,793→ 53,417 totalExercise: $4.16From: 2018-12-31Exp: 2028-05-22→ Common Stock (16,790 underlying) - Exercise/Conversion
Stock option (right to buy)
2025-12-15−8,417→ 0 totalExercise: $4.16From: 2018-12-31Exp: 2028-05-22→ Common Stock (8,417 underlying)
Footnotes (3)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.
- [F2]The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018.